Get started
Work

OA15.02 Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations

Year: 2021
Type: conference-abstract
DOI: 10.1016/j.jtho.2021.08.083
Authors: P. Janne, M. Wang, P. Mitchell, J. Fang, W. Nian, C. Chiu, J. Zhou, Y. Zhao, W. Su, D.R. Camidge, T. Yang, V. Zhu, M. Millward, Y. Fan, W. Huang, Y. Cheng, L. Jiang, D. Brungs, L. Bazhenova, C.K. Lee, B. Gao, S. Qi, X. Yu, C. Deng, K. Chen, X. Ye, L. Zheng, Z. Yang, J.C. Yang
Institutions: Dana-Farber Cancer Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Austin Hospital, Peking University Cancer Hospital, Chongqing Cancer Hospital, Taipei Veterans General Hospital, First Affiliated Hospital Zhejiang University, Henan Cancer Hospital, National Cheng Kung University Hospital, University of Colorado Cancer Center, Taichung Veterans General Hospital, University of California, Irvine Medical Center, Linear Clinical Research, Zhejiang Cancer Hospital, Chi Mei Medical Center, Jilin Province Tumor Hospital, Shanghai Chest Hospital, Wollongong Hospital, Moores Cancer Center, St George Hospital, Blacktown & Mount Druitt Hospital, Dizal (Jiangsu) Pharmaceutical Co., Ltd. (China), National Taiwan University Hospital
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3206419792
Cites:
Cited by: 6
Related to: 10